Interest of lignans in prevention and treatment of cancers;Intérêt des lignanes dans la prévention et le traitement de cancers

Medecine/Sciences

Volumn 24, Issue 5, 2008, Pages 511-519

  Lamblin, Frédéric ^a   Hano, Christophe ^a   Fliniaux, Ophélie ^b   Mesnard, François ^b   Fliniaux, Marc André ^b   Lainé, Éric ^a  

^a Centre Hospitalier de Chartres   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOFOS; ETOPOSIDE; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; FLAX; HYPTIS; JUNIPERUS; LINSEED; LUNG CANCER; NONHUMAN; PODOPHYLLUM; PODOPHYLLUM HEXANDRUM; REVIEW;

ANTHRISCUS; DYSOSMA; HYPTIS; JUNIPERUS; LINUM; LINUM USITATISSIMUM; MAMMALIA; PODOPHYLLUM PELTATUM; SINOPODOPHYLLUM HEXANDRUM;

EID: 44949087614     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2008245511     Document Type: Review

References (43)

1. Smeds AI, Eklund PC, Sjöholm RE, et al. Quantification of a broad spectrum of lignons in cereals, oilseeds, and nuts. J Agric Food Chem 2007 ; 55 : 1337-46.
2. Hall C III, Tulbek M, Xu, Y. Flaxseed. Adv Food Nutr Res 2006 ; 51 : 1-97.
3. Lainé E, Hano C, Lamblin F. Les lignanes phyto- œstrogènes du lin sont ils des bienfaiteurs méconnus ? Phytothérapie 2007 ; 5 : 121-8.
4. Cho JY, Kim AR, Yoo ES, et al. Immunomodulatory effect of arctigenin, a lignan compound, on tumour necrosis factor-α and nitric oxide production and lymphocyte proliferation J Pharm Pharmacol 1999 ; 51 : 1267-73.
5. Adlercreutz H. Phyto-cestrogens and cancer. Lancet Oncology 2002 ; 6 : 364-73.
6. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993 ; 44 : 147-53.
7. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005 ; 94 : 461-7.
8. Martin ME, Haourigui M, Pelissero C, et al. Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 1996 ; 58 : 429-36.
9. Schottner M, Spiteller G. Lignans interfering with 5alpha- dihydrotestosterone binding to human sex hormone-binding globulin. J Nat Prod 1998 ; 61 : 119-21.
10. Li D, Yee JA, Thompson LU, Yan L. Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Lett 1999 ; 142 : 91-6.
11. Bylund A, Saarinen N, Zhang JX, et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med (Maywood) 2005 ; 230 : 217-23.
12. Thompson LU, Chen JM, Li T, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 2005 ; 11 : 3828-35.
13. Danbara N, Yuri T, Tsujita-Kyutoku M, et al. Enterolactone induces apoptosis and inhibits growth of Colo 201 human colon cancer cells both in vitro and in vivo. Anticancer Res 2005 ; 25 : 2269-76.
14. Magee PJ, McGlynn H, Rowland. Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett 2004 ; 208 : 35-41.
15. Chen J, Thompson LU. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion, and migration in vitro. Br Can Res Treat 2003 ; 80 : 163-70.
16. Bergman Jungestrom M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007 ; 13 : 1061-7.
17. Prasad K. Hydroxyl radical-scavenging property of secoisolariciresinol diglucoside (SDG) isolated from flax-seed. Mol Cell Biochem 1997 ; 168 : 117-23.
18. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 1999 ; 202 : 91-100.
19. Imbert F. Discovery of podophyllotoxin. Biochimie 1998 ; 80 : 207-22.
20. Canel C, Moraes RM, Dayan FE, Ferreira D. Podophyllotoxin. Phytochemistry 2000 ; 54 : 115-20.
21. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer? Lung Cancer 2007 ; 57 : 30-4.
22. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer : have we made any progress over the last 25 years? The Oncologist 2007 ; 12 : 1096-104.
23. Sung PA, Libura J, Richardson C. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations : new insights and new questions. DNA Repair 2006 ; 5 : 1109-18.
24. Guenfoudi-Roullaud MP, Menat C, Girard F, et al. Etoposide et risque leucémogène. J Pharm Clin 1998 ; 17 : 71-3.
25. Schacter L. Etoposide phosphate : what, why, where, and how? Semin Oncol 1996 ; 23 : 1-7.
26. Hande K. Topoisomerase II inhibitors. Update Cancer Ther 2006 ; 1 : 3-15.
27. Champoux JJ. DNA topoisomerases : structure, function, and mechanism. Annu Rev Biochem 2001 ; 70 : 369-413.
28. Wang JC. Cellular roles of DNA topoisomerases : a molecular perspective. Nat Rev Mol Cell Biol 2002 ; 3 : 430-40.
29. Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 2007 ; 104 : 11014-9.
30. Leroy D, Kajava AV, Frei C, Gasser SM. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 2001 ; 40 : 1624-34.
31. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007 ; 252 : 9-18.
32. Cosse JP, Sermeus A, Vannuvel K, et al. Differential effects of hypoxia on etoposide induced apoptosis according to the cancer lines. Mol Cancer 2007 ; 6 : 61.
33. 2 arrest in response to topoisomerase II inhibitors the Role of p53. Cancer Res 2003 ; 63 : 4074-81.
34. Bjørling-Poulsen M, Issinger OG. CDNA array analysis of alterations in gene expression in the promyelocytic leukemia cell line, HL-60, after apoptosis induction with etoposide. Apoptosis 2003 ; 8 : 377-88.
35. Okada Y, Tosaka A, Nimura Y, et al. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 2001 ; 272 : 141-8.
36. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007 ; 1775 : 237-62.
37. Castro MA, Miguel del Corral JM, Gordaliza M, et al. Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin J Med Chem 2004 ; 47 : 1214-22.
38. Magedov IV, Manpadi M, Van Slambrouck S, et al. Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis. J Med Chem 2007 ; 50 : 5183-92.
39. Wiltermann AM, Bender RP, Godfrey M, et al. Topoisomerase II-drug inteaction domains : identification of substituents on etoposide that interact with the enzyme. Biochemistry 2007 ; 46 : 8217-25.
40. Zhang FM, Yao XJ, Tu YQ. Synthesis and biological evaluation of new 4β-5-Fu-substituted 4′-demethylepipodophyllotoxin derivatives. Molecules 2006 ; 11 : 849-57.
41. Medarde M, Ramos AC, Caballero E, et al. A New approach to the synthesis of podophyllotoxin based on epimerization reactions. Tetrahedron Lett 1996 ; 37 : 2663-66.
42. Farkya S, Bisaria VS, Srivastava AK. Biotechnological aspects of the production of the anticancer drug podophyllotoxin. Appl Microbiol Biotechnol 2004 ; 65 : 504-19
43. Gordaliza M, García PA, Miguel del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin : distribution, sources, applications and new cytotoxic derivatives Toxicon 2004 ; 44 : 441-59